Home PoliticsAmerica Coronavirus Variants in USA

Nearly 1,000 infection cases of coronavirus variants have been reported in a total of 44 U.S. states, according to the latest data of the U.S. Centers for Disease Control and Prevention (CDC).

The vast majority of these cases, 981, were caused by the variant known as B.1.1.7, which was originally detected in Britain.

There were 13 cases of a new strain initially discovered in South Africa, called B.1.351, and three cases of the P.1 strain first discovered in Brazil.

These are the three dominant coronavirus variants currently spreading in the United States, according to the CDC.

Numerous SARS-CoV-2 variants have emerged over the last several months, attracting the attention of health and science experts worldwide.

The B.1.1.7 and B.1.351 concern scientists because of emerging data suggesting their increased transmissibility, according to an article published Friday in the Journal of the American Medical Association (JAMA).

Variants can carry several different mutations, but changes in the spike protein of the virus, used to enter cells and infect them, are especially concerning. Changes to this protein may cause a vaccine to be less effective against a particular variant, according to the study written by Anthony Fauci, the nation’s top infectious disease expert, and other researchers.

The authors note that the B.1.351 variant may be partially or fully resistant to certain SARS-CoV-2 monoclonal antibodies currently authorized for use as therapeutics in the United States.

Healthcare workers help a patient in the “COVID Area” of the Beverly Hospital in Montebello City, California, the United States, Jan. 22, 2021. (Xinhua)

A new SARS-CoV-2 variant, CAL.20C, has been detected in southern California amid a surge in local infections and is spreading through and beyond the United States, according to another research letter published in JAMA.

By Jan. 22, the variant had grown to account for 35 percent of all coronavirus strains in California and 44 percent of all samples in the southern part of the state and had been detected in 26 states as well as other countries, according to the study by researchers at Cedars-Sinai Medical Center in Los Angeles.

The recognition of all new variants, including the novel emergent strain in California, requires systematic evaluation, according to the researchers. The rise of these variants is a reminder that as long as SARS-CoV-2 continues to spread, it has the potential to evolve into new variants.

The fight against SARS-CoV-2 and COVID-19 will require robust surveillance, tracking, and vaccine deployment worldwide, said the studies.

Researchers also note the need for a pan-coronavirus vaccine. Once researchers know more about how the virus changes as it spreads, it may be possible to develop a vaccine that protects against most or all variants.

The United States has recorded over 27.5 million cases with more than 481,600 related deaths as of Saturday afternoon, according to the real-time count kept by Johns Hopkins University.

You may also like

logo-white

Your Trusted Source for Capital Markets & Related News

© 2024 LiveTradingNews.com – For The Traders, By The Traders – All Right Reserved.

The information contained on this website shall not be construed as (i) an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities or services, (ii) investment, legal, business or tax advice or an offer to provide such advice, or (iii) a basis for making any investment decision. An offering may only be made upon a qualified investor’s receipt not via this website of formal materials from the Knightsbridge an offering memorandum and subscription documentation (“offering materials”). In the case of any inconsistency between the information on this website and any such offering materials, the offering materials shall control. Securities shall not be offered or sold in any jurisdiction in which such offer or sale would be unlawful unless the requirements of the applicable laws of such jurisdiction have been satisfied. Any decision to invest in securities must be based solely upon the information set forth in the applicable offering materials, which should be read carefully by qualified investors prior to investing. An investment with Knightsbridge is not suitable or desirable for all investors; investors may lose all or a portion of the capital invested. Investors may be required to bear the financial risks of an investment for an indefinite period of time. Qualified investors are urged to consult with their own legal, financial and tax advisors before making any investment. Knightsbridge is a private investment firm that offers investment services to Qualified Investors, Members and Institutions ONLY. Qualified Investors are defined as individuals who have met those Qualifications in the relevant jurisdictions. Members are defined as individuals who have been accepted into the Knightsbridge membership program. Institutions are defined as entities such as banks, pension funds, and hedge funds. If you are not a Qualified Investor, Member or Institution, you are not eligible to invest with Knightsbridge. All investments involve risk, and there is no guarantee of profit. You may lose some or all of your investment. Past performance is not indicative of future results. Knightsbridge is not a registered investment advisor, and this disclaimer should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. By accessing this website, you agree to the terms of this disclaimer. Thank you for your interest in Knightsbridge.